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Sir,
We thank Dr Jayaraj and Mr Kumarasamy (Jayaraj and Kumarasamy,
2017) for their comments on our meta-analysis (Almangush et al, 2017).
Oral tongue squamous cell carcinoma (OTSCC) has a different behaviour
compared with SCC of other subsites of the oral cavity. In the analysis of
Surveillance, Epidemiology, and End Results (SEER) database, Rusthoven
et al found that OTSCC is associated with worse survival compared with
SCC originating in other oral cavity subsites (Rusthoven et al, 2008). In
the analysis of a large cohort of another population, patients with OTSCC
were reported to have more tendency to neck failure, one of the most
consistent prognosis factors, than those with SCC of buccal mucosa (Liao
et al, 2010). Furthermore, Trivedi et al have studied the prognostic value
of many biomarkers using immunohistochemistry of buccal and tongue
carcinomas, and they concluded that these two subsites of the oral cavity
have different biological behaviours, which was reflected in their
prognostic analysis (Trivedi et al, 2011). Variations in the prognostic
significance of the histopathologic markers have also been reported
between the oral SCC subsites (Liu et al, 2017). Therefore, it is quite
common in the literature that researchers evaluate prognostic biomarkers
of OTSCC separately from other subsites of the oral cavity, in order to
have homogenous cohorts that provide more accurate data than mixed
cohorts. Accordingly, we argue that our focus on studies of OTSCC
provides a more accurate meta-analysis and more specific conclusions.
In their letter, Dr Jayaraj and Mr Kumarasamy also suggested that our
review should be more flexible to include articles of OTSCC analysed as a
subset of other sites of head and neck squamous cell carcinoma
(HNSCC). In addition, Dr Jayaraj and Mr Kumarasamy emphasised ‘‘the
histological and molecular similarities between different types of HNSCC
including OTSCC’’. We would like to point out that HNSCCs have wide
variations in clinical, histological and molecular characteristics (Kang
et al, 2015; Farsi et al, 2017). In addition, squamous cell carcinomas from
different areas of the head and neck typically have different etiological
backgrounds (Farsi et al, 2017). The above aspects make them in fact
different disease entities. Therefore, different treatment protocols have
been confirmed for various subtypes of HNSCCs. For HPVþ
oropharyngeal cancer (chemo)radiotherapy alone seems to be a feasible
treatment option, while for OTSCC (which is usually HPV ), the
therapeutic approach includes surgery and elective neck treatment even
in T1-T2N0 tumours in case of aggressive histopathologic features (e.g.
tumour invasion 44mm). It is of note that meta-analysis of SCCs from
different subsites of the head and neck has been criticised due to
heterogeneity of these subsites (Dayan & Vered, 2013).
At the end of their letter, Dr Jayaraj and Mr Kumarasamy highlighted
eukaryotic translation initiation factor 4E (eIF4E) and its overexpression
in head and neck cancer (HNC). To the best of our knowledge, the
prognostic value of eIF4E has not been studied in large cohorts of
OTSCC. Moreover, eIF4E was not mentioned in a comprehensive
systematic review and meta-analysis of OSCC biomarkers published
recently (Rivera et al, 2017). Although some studies have evaluated eIF4E
as mentioned by Dr Jayaraj and Mr Kumarasamy, systematic searches by
us (Almangush et al, 2017) and others (Rivera et al, 2017) did not find
sufficient evidence for eIF4E as an important biomarker for OSCC or
OTSCC.
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